Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference Ready to Announce with Confidence?

newsfilecorp.com
KPRX The article announces Kiora Pharmaceuticals' participation in the Oppenheimer Healthcare Life Sciences Conference. While this is a standard corporate announcement, it doesn't provide new financial data or clinical trial results, making the sentiment neutral. The company is developing therapies for retinal diseases, which is a positive area, but the immediate impact of this announcement is limited.

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.

A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration.

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:

Investors

investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284505

Source: Kiora Pharmaceuticals, Inc.

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Kiora Pharmaceuticals, Inc. or all companies in the Biotechnology, Pharmaceuticals industry.

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

2026-02-19 8:30 AM EST

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

2026-01-27 7:00 AM EST

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

2025-12-01 6:45 AM EST

Aug 29, 2025

September isn’t just back-to-school season—it’s back-to-business season. To see how companies prepare, we analyzed nearly 2,400 press releases from publicly traded companies on TMX Newsfile this summer (July 1 – August 28). The data reveals clear priorities. Financing & Capital Raises ( 25.5% ) and Product Launches & Updates ( 24.8% ) were the two most common strategies, together making up more than 50% of all announcements. But what really captures the market’s attention? Our viewership...

Economy, Business and Finance

Biotechnology

Chemicals

Pharmaceutical

Biotechnology

Pharmaceuticals